1-(Azolyl)-4-(aryl)-phthalazines: Novel potent inhibitors of VEGF receptors I and II

Chemical Biology and Drug Design

Volumn 68, Issue 5, 2006, Pages 250-255

  Kiselyov, Alexander S ^a   Semenova, Marina ^b   Semenov, Victor V ^c   Piatnitski, Evgueni L ^d  

^a CHEMDIV INC   (United States)

^b KOL TSOV INSTITUTE OF DEVELOPMENTAL BIOLOGY   (Russian Federation)

^c N D ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Adenosine triphosphate competitive kinase inhibitors; Angiogenesis; Phthalazines; Vascular endothelial growth factor receptor II

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZENE DERIVATIVE; BEVACIZUMAB; PHOSPHOTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYMATIC ASSAY; ENZYME INHIBITION; FLUORESCENCE; HUMAN; IC 50; INHIBITION KINETICS; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITORS; BINDING SITES; BINDING, COMPETITIVE; HUMANS; INHIBITORY CONCENTRATION 50; PHTHALAZINES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33845516261     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2006.00445.x     Document Type: Article

References (25)

1. Risau W. (1997) Mechanism of angiogenesis. Nature;386:671-674.
2. Klagsburn M., Moses M.A. (1999) Molecular angiogenesis. Chem Biol;6:R217-R224.
3. Hanahan D., Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell;86:353-364.
4. Eskens F. (2004) Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer;90:1-7.
5. Eskens F., Olsson A.-K., Dimberg A., Kreuger J., Claesson-Welsch L. (2006) VEGF receptor signaling-in control of vascular function. Nat Rev Mol Cell Biol;7:359-371.
6. Zachary I. (2003) VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans;31:1171-1177.
7. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov;3:391-400.
8. Saaristo A., Karpanen T., Alitalo K. (2000) Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene;19:6122-99.
9. Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med;1:27-31.
10. Fuh G., Li B., Crowley C., Cunningham B.C., Wells J.A. (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem;273:11197-11204.
11. Barleon B., Totzke F., Herzog C., Blanke S., Kremmer E., Siemeister G., Marme D., Martiny-Baron G. (1997) Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem;272:10382-10388.
12. Cherrington J.M., Strawn L.M., Shawver L.K. (2000) New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res;79:1-38.
13. Culy C. (2005) The anti-angiogenic antibody Avastin™ (Bevacizumab) has recently been approved for the treatment of colorectal cancer. Drugs Today;41:23-36.
14. Fine S.L., Martin D.F., Kirkpatrick P. (2005) The anti-angiogenic aptamer Macugen™ (Pegaptanib sodium) has recently been approved to treat neovascular age-related macular degeneration. Nat Rev Drug Discov;4:187-188.
15. Ciardello F., Caputo R., Damiano V., Caputo R., Troiani T., Vitagliano D., Carlomango F., Veneziani B.M., Fontanini G., Bianco A.R., Tortora, G. (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res;9:1546-1556.
16. Drevs J., Konerding M.A., Wolloscheck T., Wedge S.R., Ryan A.J. Ogilivie D.J., Esser N. (2004) The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis;7:347-354.
17. Hess-Stumpp H., Haberey M., Thierauch K.H. (2005) PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem;6:550-557.
18. Manley P.W., Furet P., Bold G., Bruggen J., Mestan J., Meyer T., Schnell C.R., Wood J. (2002) Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem;45:5687-5693.
19. Piatnitski E.L., Duncton M., Katoch-Rouse R., Sherman D., Kiselyov A.S., Milligan D., Balagtas C., Wong W., Kawakami J., Doody J. (2005) Aryl phthalazines: Part I: Inhibitors of the VEGF receptor II tyrosine kinase. Bioorg Med Chem Lett;15:4696-4698;
20. b) Duncton M., Piatnitski E.L., Kiselyov A. S., Milligan D., Balagtas C., Smith L. II, Katoch-Rouse R., Sherman D., Doody J. (2006) Aryl Phthalazines Part II: Inhibitors of VEGF. Receptors I and II Bioorg Med Chem Lett; 16: 1579-1581.
21. Duncton M., Piatnitski E.L., Kiselyov A.S. et al. (2006) Aryl phthalazines: Part II: Inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett;16:1579-1581.
22. Shevyakov S.V., Davydova O.I., Pershin D.G., Krasavin M., Kravchenko D.V., Kiselyov A.S., Tkachenko S.E., Ivachtchenko A.V. (2006) Natural Products as Templates for Bioactive Compound Libraries: Synthesis of Biaryl Derivatives of (±)-Vasicine. Nat Prod Res;20:735-741.
23. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.C., Villafranca J.E., Appelt K. (1999) Crystal structure of the kinase domain of human vascular Endothelial Growth Factor Receptor 2: a key enzyme in angiogenesis. Structure;7:319.
24. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The protein data bank. Nucleic Acids Res;28:235-242.
25. Jain R.K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science;307:58-62.